Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85

NCT04473690 is registered in ClinicalTrials.gov with KBio Inc as lead sponsor.

NCT NCT04473690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04473690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
Lead sponsor
KBio Inc
Phase
Phase 1/2
Overall status
Completed
Start date
December 30, 2020
Completion date
October 14, 2022
Enrollment
102 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid19